- Home
- ORGO vs EBS Comparison
ORGO vs EBS Comparison
Compare ORGO & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORGO | EBS |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.6M | 411.1M |
| IPO Year | 2016 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ORGO | EBS |
|---|---|---|
| Price | $2.40 | $8.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $8.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.7M | 595.9K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1600.00 | 125.83 |
| EPS | 0.15 | ★ 0.93 |
| Revenue | $564,169,000.00 | ★ $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | $26.27 | N/A |
| P/E Ratio | $15.90 | ★ $8.66 |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $2.21 | $4.71 |
| 52 Week High | $7.08 | $14.06 |
Technical Indicators
Market Signals| Indicator | ORGO | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 46.17 |
| Support Level | $2.26 | $7.77 |
| Resistance Level | $2.60 | $8.54 |
| Average True Range (ATR) | 0.13 | 0.32 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 43.88 | 26.92 |
Price Performance
Historical ComparisonAbout ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.